MedTrace Logo

Efficacy and Acceptability of Thermal Ablation in the Treatment of Cervical Neoplasia

NCT05453318 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2022-07-12

No results posted yet for this study

Summary

Longitudinal study in two referral centers in Morocco to evaluate the effectiveness, the acceptability and safety of thermal ablation in the treatment of cervical neoplasia.

Conditions

  • Cervical Neoplasm

Interventions

PROCEDURE

Treatment of cervical neoplasia by thermal ablation

Women screened for cervical cancer by VIA presenting lesions eligible for ablative treatment were treated by thermal ablation. The treatment consisted in applying the probe on the lesion for 45 seconds at 100 degrees Celsius, with one to up to five applications depending on the lesion size. Following treatment, women were inquired about the pain level during the procedure, their satisfaction level of the procedure and whether they would recommend this treatment to their relatives. Women had a follow-up visit at 6 weeks to assess any complication of the procedure. Women were rescreened at 12 months, to evaluate the cure rate and any long-term adverse events.

Sponsors & Collaborators

  • Referral Centre of Reproductive Health, Fez, Morocco

    collaborator UNKNOWN

  • Referral Centre of Reproductive Health, Taza, Morocco

    collaborator UNKNOWN

  • International Agency for Research on Cancer

    lead OTHER

Principal Investigators

  • Zakia GHAFFOULI, MD · Diagnosis Centre, TAZA

  • Hanane BELCADI ABBASSI, MD · Diagnosis Centre, Fez

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-17
Primary Completion
2020-08-17
Completion
2020-08-17

Countries

  • Morocco

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05453318 on ClinicalTrials.gov